Pfizer CEO Sees “Emerging Consensus” On Global Patent Protection Issues
There is an "emerging consensus" that the best approach to providing antiretroviral drug therapies to developing countries includes strong intellectual property rules, which then make product donations possible, Pfizer CEO Hank McKinnell, PhD, said
You may also be interested in...
The Pharmaceutical Research & Manufacturers of America expects TRIPS negotiations on the importation of drugs made under compulsory license to resume within several weeks
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials